- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vistagen Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.vistagen.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Shawn K. Singh
Number Of Employees: 39
Enterprise Value: $-14,854,240
PE Ratio: -1.76
Exchange/Ticker 1: NASDAQ:VTGN
Exchange/Ticker 2: N/A
Latest Market Cap: $80,525,296
BioCentury | Jul 23, 2022
Product Development
July 22 Quick Takes: VistaGen shares crumble after failure in anxiety disorder
Plus Owkin-Crick-Royal Marsden, Astellas, Vertex and more
BioCentury | May 3, 2022
Management Tracks
Jansen to retire from Pfizer
Plus Patel leaves FDA and updates from Roivant, Aldeyra, Omega and more
BioCentury | May 5, 2021
Management Tracks
Clackson joins Theseus as CEO, plus Calliditas, Cerevel, VistaGen, Escient and Shoreline
Theseus Pharmaceuticals Inc. hired Tim Clackson as president and CEO to succeed Iain Dukes, the co-founder and OrbiMed venture partner who has held the CEO role on an interim basis. Dukes will
BioCentury | Mar 31, 2021
Emerging Company Profile
Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline
Emerging Company Profile: $170M raise led by Lake Bleu gives Ji Li cash to hunt neurology, eye disorder assets
BioCentury | Oct 16, 2020
Deals
Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies
AffaMed, EverInsight will focus on ophthalmology, neurology and psychiatry drugs
BioCentury | Jun 29, 2018
Tools & Techniques
QT replacement plan
How stem cell-based assays could help fix the problem with clinical QT testing
Items per page:
1 - 10 of 51